Daiichi Sankyo takes Seattle Genetics to court as battle ove...

Big-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and what share of profits they deserve – and Daiichi Sankyo and AstraZen

Astellas gets EU approval for AML drug Xospata

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival dr

AZ/Daiichi's possible breast cancer blockbuster gets fast US...

The FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, setting up a possible launch as early as Q2 next year.

Astellas maintains lead over Daiichi Sankyo with CHMP okay f...

Daiichi Sankyo’s pexidartinib is first FDA-approved drug for...

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0;

Daiichi waits on FDA as AML drug quizartinib approved in Jap...

The Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts over the outcome of a regulatory review in the US.